Two studies have shown that romosozumab is effective for increasing bone mineral density in both men and women with osteoporosis. And due to safety concerns, Janssen has dropped out of clinical trials for fulranumab, which is being studied to treat OA pain…
Search results for: bone mineral density
The 2023 ACR Awards of Distinction
SAN DIEGO—During ACR Convergence 2023 on Nov. 11, the ACR honored a group of individuals who have made significant contributions to rheumatology research, education and patient care by announcing the recipients of the ACR’s 2023 Awards of Distinction, as well as the 2023 ACR Masters who were recognized for their contributions to the field.
ACR Releases Update to Glucocorticoid-Induced Osteoporosis Guideline
The ACR recently released an update on the prevention and treatment of glucocorticoid-induced osteoporosis.1 The guideline, which includes information on the new therapies abaloparatide and romosozumab, emphasizes the importance of shared decision making by patients and clinicians, and also gives information on the importance of sequential therapy after stopping certain osteoporotic prevention therapies. Fracture Prevention…
Glucocorticoid Use at Any Dose Increases Fracture Risk
The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.
A Medical Research Career Fueled by Curiosity
In January, Cecilia Pilar Chung, MD, MPH, began her new appointment as director of the Division of Rheumatology at the University of Miami. Previously, Dr. Chung was an associate professor of medicine at Vanderbilt University, Nashville, Tenn., for more than 10 years. At Vanderbilt, Dr. Chung built a strong research portfolio, focusing on the comparative…
Supplemental Vitamin D May Not Protect Against Fractures in Healthy Adults
Supplemental vitamin D may not significantly lower the risk of fractures in generally healthy adults compared with placebo, according to a large study by LeBoff et al.
Highlights from the ACR Review Course 2022
PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….
Challenging Cases in Osteoporosis: Tips from an Expert
Using three complicated patient cases, Kenneth G. Saag, MD, MSc, shared his expertise on osteoporosis and walked through his thought process and the literature, during a session of the 2022 ACR Education Exchange.
In Memoriam: James F. Fries, MD
James Franklin Fries was born on Aug. 25, 1938, in Normal, Ill. His mother taught middle school English and his father was a college business professor. Jim graduated from Stanford University in 1960 with a major in philosophy, and received his MD at Johns Hopkins University, Baltimore, in 1964. He pursued internal medicine and rheumatology…
At Least 1 Year on Bisphosphonates Needed for Fracture Prevention
(Reuters Health)—It takes 12.4 months of bisphosphonate therapy to prevent one nonvertebral fracture per 100 postmenopausal women with osteoporosis, a meta-analysis of randomized clinical trials suggests.1 Researchers examined data on 10 randomized clinical trials with a total of 23,384 women who had an osteoporosis diagnosis based on either existing vertebral fractures or a bone mineral…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 16
- Next Page »